Bone Material Strength Index Is Low in Patients With Cushing's Syndrome Even After Long-term Remission - Summary - MDSpire

Bone Material Strength Index Is Low in Patients With Cushing's Syndrome Even After Long-term Remission

  • By

  • Manuela Schoeb

  • Paula J C Sintenie

  • Leontine E H Bakker

  • Nienke R Biermasz

  • Femke M van Haalen

  • Michiel F Nijhoff

  • Friso de Vries

  • Elizabeth M Winter

  • Alberto M Pereira

  • Natasha M Appelman-Dijkstra

  • November 20, 2024

  • 0 min

Share

Objective:

To evaluate bone material properties in patients with Cushing's syndrome (CS) in remission compared to matched controls, focusing on the bone material strength index (BMSi).

Key Findings:
  • BMSi was significantly lower in CS patients (76.2 ± 6.7) compared to controls (80.5 ± 4.9, P < .001), indicating compromised bone material strength.
  • BMSi negatively correlated with body mass index (r = −0.354, P = .01), suggesting that higher BMI may be associated with better bone material properties.
  • No correlation was found between BMSi and fracture presence, hydrocortisone replacement use, or time since remission.
Interpretation:

Bone material properties remain compromised in CS patients even after long-term remission, indicating that BMD alone may not fully assess fracture risk, as BMSi may provide additional insights.

Limitations:
  • Cross-sectional design limits causal inferences and may not capture the full spectrum of bone health in CS patients.
  • Sample size may not represent all CS patients.
Conclusion:

Altered bone material properties in CS patients post-remission may contribute to ongoing fracture risk despite improved BMD.

Original Source(s)

Bone Material Strength Index Is Low in Patients With Cushing's Syndrome Even After Long-term Remission

  • by Manuela Schoeb, Paula J C Sintenie, Leontine E H Bakker, Nienke R Biermasz, Femke M van Haalen, Michiel F Nijhoff, Friso de Vries, Elizabeth M Winter, Alberto M Pereira, Natasha M Appelman-Dijkstra

  • November 20, 2024

Related Content

Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation

Development and Experimental Validation of an Osteoporosis Diagnosis Model Based on Disulfidoptosis-related Genes and Immune Infiltration Analysis

Assessment of bone density and microarchitecture in patients with familial partial lipodystrophy